Biodistribution, radiation dosimetry and scouting of 90Y- ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 3, 2012, Pages 512-520

  Rizvi, Saiyada N F ^a   Visser, Otto J ^a   Vosjan, Maria J W D ^a   Van Lingen, Arthur ^a   Hoekstra, Otto S ^a   Zijlstra, Josée M ^a   Huijgens, Peter C ^a   Van Dongen, Guus A M S ^a   Lubberink, Mark ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

89Zr; 90Y; Dosimetry; Ibritumomab tiuxetan; Immuno PET; Lymphoma; Molecular imaging; Radioimmunotherapy

Indexed keywords

89ZR IBRITUMOMAB TIUXETAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INDIUM 111; METHOTREXATE; PREDNISOLONE; RADIOISOTOPE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90; ZIRCONIUM DERIVATIVE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DOSIMETRY; FEMALE; HUMAN; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; SPLEEN; STEM CELL TRANSPLANTATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOMETRY; RECURRENCE; STEM CELL TRANSPLANTATION; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84859648576     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2008-5     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010;116(4 Suppl):1126-33.
3. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001;27:593-9. (Pubitemid 32401456)
4. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23. (Pubitemid 40223656)
5. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32. (Pubitemid 41742196)
6. Herold M, Dölken G, Fiedler F, Franke A, Freund M, Helbig W, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol 2003;82:77-9. (Pubitemid 36700978)
7. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9. (Pubitemid 40175970)
8. Winter JN. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 2004;5 Suppl 1:S22-6. (Pubitemid 39467702)
9. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896-902. (Pubitemid 41510771)
10. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63. (Pubitemid 34525730)
11. Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008;26:5175-82.
12. Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, et al. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol 2007;139:590-9. (Pubitemid 350043818)
13. Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94(4 Suppl):1349-57. (Pubitemid 34150898)
14. Fisher DR, Shen S, Meredith RF. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J Nucl Med 2009;50:644-52.
15. Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:1337-45. (Pubitemid 44630790)
16. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44:1271-81. (Pubitemid 39662684)
17. Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009;50:1828-36.
18. Boellaard R, Hoekstra OS, Lammertsma AA. Software tools for standardized analysis of FDG whole body studies in multi-center trials [abstract]. J Nucl Med 2008;49 (Suppl 1):159P.
19. Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004;45:1725-33. (Pubitemid 47618483)
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
21. Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, et al. Impact of rituximab treatment on (90)Y- ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med 2010;51:150-7.
22. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113:1412-21.
23. Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med 1999;40:268-76. (Pubitemid 29077089)
24. Camera L, Kinuya S, Garmestani K, Brechbiel MW, Wu C, Pai LH, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med 1994;21:640-6. (Pubitemid 24211116)
25. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labelled Herceptin. Nucl Med Biol 2002;29:599-606. (Pubitemid 34667122)
26. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898-906. (Pubitemid 46196653)
27. Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3- octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386-92. (Pubitemid 39361934)
28. ICRP-41. Nonstochastic effects of ionizing radiation. Ann ICRP 1984;14:1-33.
29. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedures guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.